Please or Sign Up to add this content to your website.

Opening Doors to Greater Awareness and Understanding for those with Moderate to Severe Ulcerative Colitis and Crohn's Disease

Please Sign In or Sign Up to download this article.

(BPT) - There are hundreds of thousands of Americans who are impacted by ulcerative colitis (UC) or Crohn’s disease (CD), the two most common forms of inflammatory bowel disease, or IBD.

UC and CD are complex, chronic diseases that cause inflammation in the gastrointestinal (GI) tract. With no known therapeutic cure for UC or CD, the aim of treatments is to achieve remission, and for patients whose treatments haven’t worked well enough, knowing all of the options is important.

Mamie, a wife and mother who was diagnosed with severe Crohn’s disease at the age of 27, is one of the many currently managing this chronic disease.

Mamie says she wishes she knew where to look for answers after receiving her diagnosis.

“There are so many people who don’t know anything about the disease, and are looking for answers,” Mamie says. “They need to create good partnerships with their doctors and find something that works for them.”

For Mamie, after trying other medications, her symptoms returned. Her doctor then suggested she try Entyvio®(vedolizumab). Entyvio works by focusing right in the GI tract to help control damaging inflammation, and is clinically proven to help many patients achieve both symptom relief as well as remission. Results for patients taking Entyvio may vary. Entyvio is a GI-focused biologic treatment option developed and approved for both moderate to severe UC and CD.

In an effort to raise awareness, Takeda Pharmaceuticals U.S.A., Inc. has launched the “Doors” campaign. Before developing the campaign, Takeda asked members of the IBD community about living with UC and CD. These insights led to the development of this campaign aimed to help elevate the conversation about and broaden the awareness and understanding of UC and CD.

Within this campaign, the imagery of the doors serves as a metaphor for the different experiences a patient may have. It’s important that patients continue to talk to their health care professionals about different options.

The “Doors” campaign is airing during nationally-televised programs across the U.S. More information is available at www.Entyvio.com.

Important Safety Information

  • Do not receive ENTYVIO if you have had an allergic reaction to ENTYVIO or any of its ingredients.
  • ENTYVIO may cause serious side effects, including:
    • Infusion and serious allergic reactions can happen while you are receiving ENTYVIO or several hours after treatment. You may need treatment if you have an allergic reaction. Tell your healthcare provider or get immediate medical help if you get any of these symptoms during or after an infusion of ENTYVIO: rash, itching, swelling of your lips, tongue, throat or face, shortness of breath or trouble breathing, wheezing, dizziness, feeling hot, or palpitations (feel like your heart is racing).
    • ENTYVIO may increase your risk of getting a serious infection. Before receiving and during treatment with ENTYVIO, tell your healthcare provider if you think you have an infection or symptoms of an infection, such as fever, chills, muscle aches, cough, shortness of breath, runny nose, sore throat, red or painful skin or sores on your body, tiredness, or pain during urination.
    • Although it has not been reported with ENTYVIO, it may be possible for a person to get progressive multifocal leukoencephalopathy (PML) (a rare, serious brain infection caused by a virus). People with weakened immune systems can get PML, which can result in death or severe disability. There is no known treatment, prevention, or cure for PML. Tell your healthcare provider right away if you have any of the following symptoms: confusion or problems thinking, loss of balance, change in the way you walk or talk, decreased strength or weakness on one side of the body, blurred vision, or loss of vision.
    • Liver problems can happen in people who receive ENTYVIO. Tell your healthcare provider right away if you have any of the following symptoms: tiredness, loss of appetite, pain on the right side of your abdomen, dark urine, or yellowing of the skin and eyes (jaundice).
  • The most common side effects of ENTYVIO include common cold, headache, joint pain, nausea, fever, infections of the nose and throat, tiredness, cough, bronchitis, flu, back pain, rash, itching, sinus infection, throat pain, and pain in extremities. These are not all the possible side effects of ENTYVIO. Call your healthcare provider for medical advice about side effects.
  • Before receiving ENTYVIO, tell your healthcare provider about all of your medical conditions, including if you: have or think you may have an infection or have infections that keep coming back; have liver problems; have tuberculosis (TB) or have been in close contact with someone with TB; have recently received or are scheduled to receive a vaccine; or if you are pregnant, breastfeeding, plan to become pregnant, or plan to breastfeed.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see accompanying full Prescribing Information, including Medication Guide for ENTYVIO.

Uses of ENTYVIO® (vedolizumab):

ENTYVIO is a prescription medicine used in adults:

  • with moderate to severe ulcerative colitis (UC) when certain other UC medicines have not worked well enough or cannot be tolerated. ENTYVIO may help to: begin reducing some symptoms, induce and maintain remission, reduce or stop the use of corticosteroids, and improve the way the lining of your large intestine looks to your healthcare provider.
  • with moderate to severe Crohn’s disease (CD) when certain other CD medicines have not worked well enough or cannot be tolerated. ENTYVIO may help to: begin reducing some symptoms, achieve remission, and reduce or stop the use of corticosteroids.

More information about the “Doors” campaign and Mamie’s story can be found on the Entyvio website, www.Entyvio.com.

 Upload a clip